<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Five, repeatedly transfused, patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) or RA with ringed sideroblast (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) subtypes of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), with serum ferritin (SF) levels of &gt; 2,000 microg/L, and one female with Hb E [beta26(B8)<z:chebi fb="0" ids="29973,30652">Glu --</z:chebi>&gt; Lys]/<z:e sem="disease" ids="C0271980" disease_type="Disease or Syndrome" abbrv="">beta0-thalassemia</z:e> (thal) with an SF level of 1,760 microg/ L, were treated with deferiprone (L1) at the dose of 4-6 g per day for at least 26 months </plain></SENT>
<SENT sid="1" pm="."><plain>Beginning in the second month, <z:hpo ids='HP_0000001'>all</z:hpo> patients received recombinant human erythropoietin (rHuEPO) at the dose of 150 IU/kg thrice weekly, subcutaneously for 24 months </plain></SENT>
<SENT sid="2" pm="."><plain>A significant increase in iron excretion after combined administration of L1 and rHuEPO compared to treatment with L1 as a single agent, was observed in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>The amount of excreted iron in urine ranged from 7.5 to almost 20 mg per day </plain></SENT>
<SENT sid="4" pm="."><plain>In one patient, a response to rHuEPO resulted in transfusion independence and her SF decreased from 2086 to 879 microg/L </plain></SENT>
<SENT sid="5" pm="."><plain>In four <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients, who remained dependent on red blood cell (RBC) transfusions, simultaneous administration of L1 and rHuEPO enabled the stabilization of SF levels, despite continuing iron load from the transfusions </plain></SENT>
<SENT sid="6" pm="."><plain>Combined administration of rHuEPO and oral iron <z:chebi fb="0" ids="38161">chelators</z:chebi> may potentiate mobilization of storage iron and maintain iron balance in transfusion-dependent iron overloaded early <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>